Every 10-Q that Altimmune, Inc. (ALT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ALT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALT filings page.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on liver diseases, led by its dual glucagon/GLP-1 agonist pemvidutide for MASH, AUD and ALD. For the quarter ended June 30, 2026, it reported a net loss of $22.8 million and a six‑month net loss of $45.4 million, driven by research and development expenses of $34.8 million and general and administrative expenses of $15.6 million for the first half of 2026.
Liquidity strengthened significantly: total assets were $527.2 million, including $63.1 million of cash, cash equivalents and restricted cash, $263.3 million in short‑term investments and $192.2 million in long‑term investments, supported by a January 2026 registered direct offering and an April 2026 underwritten offering that together generated about $281.4 million in net equity proceeds. Term loan principal outstanding remained at $35.0 million.
Operationally, pemvidutide received FDA Breakthrough Therapy Designation for MASH, a global PERFORMA Phase 3 MASH trial was initiated with a 52‑week readout expected in 2029, a Phase 2 AUD trial met its primary endpoint with positive topline data, and enrollment in the RESTORE Phase 2 ALD trial was completed. Altimmune also plans to relocate its headquarters to Morristown, New Jersey under a five‑year lease with annual rent of approximately $0.3 million.
Altimmune, Inc. reported another quarter of operating losses as it continues to advance its liver disease pipeline. For the three months ended March 31, 2026, the company generated no product revenue and recorded a net loss of $22.6 million, compared with $19.6 million a year earlier, driven by research and development spending of $16.2 million and general and administrative expenses of $8.1 million.
Altimmune’s balance sheet strengthened meaningfully, with cash, cash equivalents, restricted cash and short‑term investments totaling $331.6 million and total liabilities of $51.6 million at quarter end, supported by recent equity raises including a January 2026 registered direct offering and an April 2026 underwritten offering that brought in net proceeds of about $211.2 million and added common stock warrants with potential additional gross proceeds of $225 million if fully exercised.
The company is preparing its global PERFORMA Phase 3 trial of lead candidate pemvidutide in MASH, while running Phase 2 studies in alcohol use disorder and alcohol‑associated liver disease. With accumulated deficit of $672.0 million and ongoing negative operating cash flow, Altimmune remains dependent on its substantial cash reserves and capital markets access to fund these long, expensive clinical programs.
Altimmune reported Q3 2025 results with a net loss of $19.0 million as operating expenses declined versus last year. Research and development was $15.0 million, reflecting lower MASH trial spend, while general and administrative was $5.9 million.
Liquidity strengthened. Cash, cash equivalents, restricted cash and short‑term investments totaled $210.8 million as of September 30, 2025. The company raised $112.1 million year‑to‑date via at‑the‑market sales and drew a $15.0 million first tranche under a term loan. Subsequent to quarter‑end, Altimmune raised $33.8 million more through the ATM and amended its Hercules facility to $125.0 million, drawing a second $20.0 million tranche; the amended loan bears the greater of 9.70% or prime plus 2.45% with a 30‑month interest‑only period.
Pipeline updates noted 24‑week IMPACT Phase 2b MASH topline results, Fast Track designation for pemvidutide in AUD, and ongoing Phase 2 trials in AUD and ALD. Shares outstanding were 104,254,173 as of October 31, 2025.
Altimmune reported strong clinical topline results from its IMPACT Phase 2b MASH trial, where weekly pemvidutide produced MASH resolution rates of 59.1% (1.2 mg) and 52.1% (1.8 mg) versus 19.1% for placebo (p<0.0001 for both doses). Fibrosis improvement by conventional ITT analysis was not statistically different, but an AI-based analysis showed a larger fibrosis reduction signal (30.6% of subjects on 1.8 mg achieved ≥60% fibrosis reduction versus 8.2% on placebo, p<0.001). Pemvidutide also drove mean weight loss of 5.0% and 6.2% at 1.2 mg and 1.8 mg versus 1.0% for placebo, and safety/tolerability appeared favorable with low discontinuation rates.
On the balance sheet, cash and equivalents were $183.1M at June 30, 2025, the company drew $15.0M of a $100M term loan facility (effective interest rate 14.4%), and generated net proceeds of $72.6M from at-the-market equity offerings in the period plus an additional $12.8M raised in July. The company recorded a six-month net loss of $41.7M and has an accumulated deficit of $603.1M. A class action alleging securities law violations was filed on August 5, 2025.